Science & Enterprise subscription

Follow us on Twitter

  • HBCUs still hand out more bachelor's degrees in STEM fields to Blacks than traditionally white institutions, but no… https://t.co/xW2ICnR09b
    about 18 hours ago
  • Special to Science and Enterprise ... HBCUs Still Putting Blacks in STEM by @crparks3 https://t.co/Osm8eeUaM2… https://t.co/SOiQkh7SO1
    about 18 hours ago
  • A clinical trial in Canada is evaluating medical cannabis products as treatments for chronic pain with participants… https://t.co/nQ9fsR2oBP
    about 23 hours ago
  • New post on Science and Enterprise: Cannabis Assessed for Pain in Real-World Trial https://t.co/lW8LF0XDog #Science #Business
    about 23 hours ago
  • New York Times ... These Scientists Raced to Find a Covid-19 Drug. Then the Virus Found Them. https://t.co/icA7EgJGNV
    about 1 day ago

Please share Science & Enterprise

Johns Hopkins, Eisai to Collaborate on New Brain Drugs

Brain scan (National Institute of Mental Health)

(National Institute of Mental Health)

Johns Hopkins University (JHU) in Baltimore and Eisai, a pharmaceutical company in Tokyo, will collaborate on research for discovery of drugs for brain conditions such as schizophrenia, pain, brain tumors and Alzheimer’s disease. The partnership will be part of the NeuroTranslational Program in JHU’s Brain Science Institute.

The Brain Science Institute researches questions about brain development and function to understand the mechanisms of brain disease. The NeuroTranslational Program connects commercial drug-discovery scientists with Johns Hopkins faculty to develop discoveries from JHU neuroscience labs into treatments neurological and psychiatric disorders.

Under the agreement, JHU will provide Eisai with new therapeutic targets in the central and peripheral nervous system discovered by JHU scientists. Using assays developed and validated by the NeuroTranslational Program, Eisai will conduct high-throughput screening of its chemical libraries to identify compounds that interact with these targets.

The goal of the collaboration is to identify clinical candidates and advance them to investigational drug-enabling studies. Eisai will have the option to enter into an agreement to develop and commercialize the new chemical compounds, and will pay upfront milestone and royalty payments on each selected drug discovery target.

Read more: Hopkins, Walgreens to Partner on Research, Outcome Protocols

*     *     *

Please share Science & Enterprise ...

Comments are closed.